Skip to main content

Table 1 Clinicopathological features of reactive lymphoid hyperplasia of the liver

From: A case of reactive lymphoid hyperplasia of the liver in a patient with autoimmune hepatitis

Variables

n = 76

Percentage

Clinical characteristics

 Age (ave, range)

56.7 (15–85)

 

 Sex

  

  Male

5

6.6

  Female

71

93.4

 Liver diseases

 

35.5

  Viral hepatitis B

6

 

  Viral hepatitis C

2

 

  Primary biliary cirrhosis

14

 

  Non-alcoholic steatohepatitis

2

 

  Autoimmune hepatitis

3

 

 Autoimmune disorders

 

17.1

  Chronic thyroiditis

4

 

  Sjögren’s syndrome

3

 

  Rheumatoid arthritis

1

 

  Takayasu disease

1

 

  Antiphospholipid syndrome

1

 

  CREST syndrome

1

 

  Immunodeficiency

2

 

 Malignant tumor

 

27.6

  Colon cancer

6

 

  Gastric cancer

5

 

  Renal cell carcinoma

4

 

  Cervical cancer

1

 

  Thyroid cancer

1

 

  Bile duct cancer

1

 

  Pancreatic cancer

1

 

  Ovarian cancer

1

 

  GIST

1

 

 Number of nodules

  Solitary

61

84.7

  Multiple

11

15.3

 Nodule size (ave, range) (mm)

  < 20

65

81.3

  ≥ 20

15

18.7

 Location

  Rt. lobe

39

62.9

  Lt. lobe

15

24.2

  Caudate lobe

3

4.8

  Bilobar

5

8.1

 Preoperative diagnosis

  

  Hepatocellular carcinoma

31

53.4

  Cholangiocellular carcinoma

4

6.9

  Metastatic

12

20.7

  Malignant tumor

7

12.1

  Others

4

6.9

 Treatment

  Operation

63

82.9

  Biopsy

8

10.5

  Transplantation

3

3.9

  Others

2

2.6

Imaging findings (described)

 US

  

  Hypo

39

51.3

  Iso

1

1.3

  Unknown

36

47.4

 CT (plain)

  

  Low

29

38.2

  Not detected

2

2.6

  Unknown

45

59.2

 CT (arterial phase)

  Enhanced

15

19.7

  Slightly enhanced

15

19.7

  Perinodular enhancement

9

11.8

  Not enhanced

5

6.6

  Unknown

32

42.1

 CT (portal or delay phase)

  

  Washout

23

30.3

  Perinodular enhancement

8

10.5

  Not enhanced

4

5.3

  Others

5

6.6

  Unknown

36

47.4

 MRI (T1WI)

  Hypo

42

55.3

  Slightly hypo

4

5.3

  Unknown

30

39.5

 MRI (T2WI)

  Hyper

38

50.0

  Slightly hyper

5

6.6

  Iso

3

3.9

  Unknown

30

39.5

MRI (arterial phase)

 Enhanced

13

17.1

 Slightly enhanced

14

18.4

 Perinodular enhancement

8

10.5

 Others

3

3.9

 Unknown

38

50.0

MRI (portal or delay phase)

 Washout

19

25.0

 Perinodular enhancement

8

10.5

 Others

3

3.9

 Unknown

46

60.5

 PET

  Positive

8

10.5

   SUV max (ave, range, n = 6)

4.9(3.4–6.7)

 

  Negative

2

2.6

  Unknown

66

86.8